ASX 200
Team Veye   April 07, 2026

Telix surges buoyed by revenue growth, pipeline advancement

Team Veye   April 07, 2026
Get your Free Report on Top 5 ASX stocks for 2026

Telix Pharmaceuticals Limited is showing stable progress with improving revenue and ongoing development in its drug pipeline. The latest updates show the business is moving forward with both commercial growth and regulatory advancements.

Telix Pharmaceuticals Limited (ASX: TLX)Β 

on 7 April 2026 informed that the revenue generated in Q1 was US$230 million which was a rise of 11% from the last quarter. The precision Medicine brought in US$186 million with 16% growth. This shows stable demand for its core imaging products and suggests the company is maintaining strong commercial momentum early in the year.

The update also showed progress in its prostate cancer therapy study. The Phase 3 ProstACT trial for TLX591-Tx met early safety and dosing goals without new concerns. This indicates the treatment is moving forward as planned. It reflects stable development progress which may support future approval if later trial stages remain consistent.

Pipeline advancement continued with regulatory activity across regions. The submission process of TLX101-Px for imaging brain tumors was restarted at the FDA of the United States while European approval filing was completed. In China, TLX591-Px was accepted for review. These steps show active growth into key markets and recommend the company is pushing to expand its global presence.

Earlier on March 16, 2026, TLX confirmed the FDA resubmission of TLX101-Px with added data to address prior questions. The drug has special designations for rare disease and faster review. This highlights its potential importance in brain cancer care and shows the company is working to resolve earlier gaps to move closer to approval.

(Source: Company Report)

Get your FREE ASX stock report

Discover our latest ASX share ideas and ongoing insights – so you're not guessing with your money

πŸ’¬

Get Your Free Report on Top 5 ASX Stocks on WhatsApp

Instant Access. No Credit Card Required.

Receive on WhatsApp

Checkout Our Recommendation for free - 7 days free trial

Start Free Trial
7‑day free trial

ASX Stock Research & Recommendations β€” 7‑day free trial

Independent, analyst‑driven insights.

  • Stock of the week report
  • Daily Analysis Report
  • No credit card required
General information only. Not financial advice.

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...

Latest Article


Post Image
Team Veye

Best ASX Tech Stocks to Buy

June 05, 2026
Post Image
Team Veye

Top income stocks Australia

June 05, 2026
Post Image
Team Veye

ASX gold mining stocks 2026

June 05, 2026

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.